| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
This compound does not have a specific biological target. Its function is as a lipid excipient or building block. It is used in the preparation of cationic lipids for the delivery of nucleic acids, such as siRNA, to suppress the expression of target genes like the hepatitis B virus gene.
|
|---|---|
| ln Vitro |
As an excipient, 2-Hexyldecanoic acid has no direct biological activity. Its activity is structural; it is incorporated into larger lipid structures to facilitate drug delivery. It has been shown to inhibit the growth of prostate cancer cells and possess antibacterial activity against gram-positive bacteria.
|
| ln Vivo |
This compound is not a drug with intrinsic in vivo activity. Its in vivo function is realized when it is used to formulate a therapeutic agent, such as in lipid nanoparticles for nucleic acid delivery. It can also serve as an aerolysin inhibitor to prevent bacterial pathogens.
|
| Enzyme Assay |
As a chemical compound, there is no biological assay for 2-Hexyldecanoic acid's "activity." Its utility is demonstrated in formulation studies. The ability of the lipid to form stable nanoparticles or liposomes and efficiently encapsulate and deliver nucleic acids is assessed.
|
| Cell Assay |
There are no cell-based assays for the compound itself. Its efficacy is evaluated in cell-based assays using the final lipid nanoparticle formulation. These assays measure cellular uptake of the nucleic acid cargo and the resulting gene silencing or protein expression effects.
|
| Animal Protocol |
Animal studies are performed with the final therapeutic formulation (e.g., lipid nanoparticles containing siRNA). These studies assess the biodistribution, efficacy (e.g., suppression of a target gene), and safety of the delivery system.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are determined for the formulated drug (e.g., lipid nanoparticles), not for the fatty acid alone. 2-Hexyldecanoic acid contributes to the stability and compatibility of the formulation, which can enhance the delivery and absorption of active compounds through the skin in topical applications.
|
| Toxicity/Toxicokinetics |
2-Hexyldecanoic acid is generally considered safe for its intended use as an excipient. However, it can cause contact dermatitis in some individuals. Safety data is typically associated with the final formulation rather than the individual component.
|
| Additional Infomation |
Hexyldecanoic acid is a medium-chain fatty acid.
2-Hexyldecanoic acid is a versatile research chemical used in lipid-based drug delivery systems for nucleic acids, such as siRNA for gene silencing. It is also used as an excipient in topical pharmaceutical formulations to enhance skin penetration. It is an important building block for creating complex lipid structures. |
| Molecular Formula |
C16H32O2
|
|---|---|
| Molecular Weight |
256.43
|
| Exact Mass |
256.24
|
| CAS # |
25354-97-6
|
| PubChem CID |
32912
|
| Appearance |
Colorless to light yellow liquid（Density：0.88 g/cm3）
|
| Density |
0,88 g/cm3
|
| Boiling Point |
165-168°C 2mm
|
| Melting Point |
10°C
|
| Flash Point |
174°C
|
| Vapour Pressure |
1.6E-06mmHg at 25°C
|
| Index of Refraction |
1.4460
|
| LogP |
5.408
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
18
|
| Complexity |
190
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C(CCCCCCCC)C(O)=O)CCCCC
|
| InChi Key |
JMOLZNNXZPAGBH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H32O2/c1-3-5-7-9-10-12-14-15(16(17)18)13-11-8-6-4-2/h15H,3-14H2,1-2H3,(H,17,18)
|
| Chemical Name |
2-hexyldecanoic acid
|
| Synonyms |
Pentadecane-7-carboxylic Acid; Isopalmitic Acid; 2-Hexyldecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~389.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8997 mL | 19.4985 mL | 38.9970 mL | |
| 5 mM | 0.7799 mL | 3.8997 mL | 7.7994 mL | |
| 10 mM | 0.3900 mL | 1.9498 mL | 3.8997 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
